Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Hospital Variation in Cancer Treatments and Survival OutComes of Advanced Melanoma Patients: Nationwide Quality Assurance in The Netherlands.
van Breeschoten J, van den Eertwegh AJM, de Wreede LC, Hilarius DL, van Zwet EW, Haanen JB, Blank CU, Aarts MJB, van den Berkmortel FWPJ, de Groot JWB, Hospers GAP, Kapiteijn E, Piersma D, van Rijn RS, Stevense-den Boer MAM, van der Veldt AAM, Vreugdenhil G, Boers-Sonderen MJ, Suijkerbuijk KPM, Wouters MWJM. van Breeschoten J, et al. Cancers (Basel). 2021 Oct 11;13(20):5077. doi: 10.3390/cancers13205077. Cancers (Basel). 2021. PMID: 34680228 Free PMC article.
Nationwide Outcomes of Advanced Melanoma According to BRAFV600 Status.
van Breeschoten J, Wouters MWJM, de Wreede LC, Hilarius DH, Haanen JB, Blank CU, Aarts MJB, van den Berkmortel FWPJ, de Groot JB, Hospers GAP, Kapiteijn E, Piersma D, van Rijn RS, Suijkerbuijk KPM, Blokx WAM, Ten Tije AJ, van der Veldt AAM, Vreugdenhil G, Boers MJ, van den Eertwegh AJM. van Breeschoten J, et al. Among authors: van den eertwegh ajm, van der veldt aam, van den berkmortel fwpj, van rijn rs. Am J Clin Oncol. 2021 Feb 1;44(2):82-89. doi: 10.1097/COC.0000000000000786. Am J Clin Oncol. 2021. PMID: 33332931
First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis.
van Breeschoten J, Wouters MWJM, Hilarius DL, Haanen JB, Blank CU, Aarts MJB, van den Berkmortel FWPJ, de Groot JB, Hospers GAP, Kapiteijn E, Piersma D, van Rijn RS, Suijkerbuijk KPM, Blokx WAM, Tije BJT, Veldt AAMV, Vreugdenhil A, Boers-Sonderen MJ, van den Eertwegh AJM. van Breeschoten J, et al. Among authors: van den eertwegh ajm, van den berkmortel fwpj, van rijn rs. Br J Cancer. 2021 Mar;124(7):1222-1230. doi: 10.1038/s41416-020-01229-1. Epub 2021 Jan 26. Br J Cancer. 2021. PMID: 33495600 Free PMC article.
Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease : A Cohort Study.
van der Kooij MK, Suijkerbuijk KPM, Aarts MJB, van den Berkmortel FWPJ, Blank CU, Boers-Sonderen MJ, van Breeschoten J, van den Eertwegh AJM, de Groot JWB, Haanen JBAG, Hospers GAP, Piersma D, van Rijn RS, Ten Tije AJ, van der Veldt AAM, Vreugdenhil G, van Zeijl MCT, Wouters MWJM, Dekkers OM, Kapiteijn E. van der Kooij MK, et al. Among authors: van breeschoten j, van den eertwegh ajm, van der veldt aam, van den berkmortel fwpj, van zeijl mct, van rijn rs. Ann Intern Med. 2021 May;174(5):641-648. doi: 10.7326/M20-3419. Epub 2021 Feb 16. Ann Intern Med. 2021. PMID: 33587686
Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis.
van Breeschoten J, Wouters MWJM, Hilarius DL, Haanen JB, Blank CU, Aarts MJB, van den Berkmortel FWPJ, de Groot JB, Hospers GAP, Kapiteijn E, Piersma D, van Rijn RS, Suijkerbuijk KPM, Blokx WAM, Ten Tije BJ, van der Veldt AAM, Vreugdenhil A, Boers-Sonderen MJ, van den Eertwegh AJM. van Breeschoten J, et al. Among authors: van den eertwegh ajm, van der veldt aam, van den berkmortel fwpj, van rijn rs. Br J Cancer. 2021 May;124(10):1746. doi: 10.1038/s41416-021-01312-1. Br J Cancer. 2021. PMID: 33723402 Free PMC article. No abstract available.
Adjuvant treatment for melanoma in clinical practice - Trial versus reality.
de Meza MM, Ismail RK, Rauwerdink D, van Not OJ, van Breeschoten J, Blokx WAM, de Boer A, van Dartel M, Hilarius DL, Ellebaek E, Bonenkamp HJ, Blank CU, Aarts MJB, van Akkooi ACJ, van den Berkmortel FWPJ, Boers-Sonderen MJ, de Groot JWB, Haanen JB, Hospers GAP, Kapiteijn EW, Piersma D, van Rijn RS, van der Veldt AAM, Vreugdenhil A, Westgeest HM, van den Eertwegh AJM, Suijkerbuijk KPM, Wouters MWJM. de Meza MM, et al. Among authors: van akkooi acj, van not oj, van breeschoten j, van dartel m, van den eertwegh ajm, van der veldt aam, van den berkmortel fwpj, van rijn rs. Eur J Cancer. 2021 Nov;158:234-245. doi: 10.1016/j.ejca.2021.08.044. Epub 2021 Sep 29. Eur J Cancer. 2021. PMID: 34600790 Free article.
The unfavorable effects of COVID-19 on Dutch advanced melanoma care.
van Not OJ, van Breeschoten J, van den Eertwegh AJM, Hilarius DL, De Meza MM, Haanen JB, Blank CU, Aarts MJB, van den Berkmortel FWPJ, de Groot JWB, Hospers GAP, Ismail RK, Kapiteijn E, Piersma D, van Rijn RS, Stevense-den Boer MAM, van der Veldt AAM, Vreugdenhil G, Boers-Sonderen MJ, Blokx WAM, Suijkerbuijk KPM, Wouters MWJM. van Not OJ, et al. Among authors: van breeschoten j, van den eertwegh ajm, van der veldt aam, van den berkmortel fwpj, van rijn rs. Int J Cancer. 2022 Mar 1;150(5):816-824. doi: 10.1002/ijc.33833. Epub 2021 Oct 22. Int J Cancer. 2022. PMID: 34605003 Free PMC article.
Response to: Effect of dose reductions on clinical outcomes, or of outcomes on dose reductions?
Ismail RK, van Breeschoten J, Wouters MWJM, van Dartel M, van der Flier S, Reyners AKL, de Graeff P, Pasmooij AMG, de Boer A, Broekman KE, Hilarius DL. Ismail RK, et al. Among authors: van breeschoten j. Breast. 2022 Apr;62:180. doi: 10.1016/j.breast.2022.01.011. Epub 2022 Jan 29. Breast. 2022. PMID: 35190238 Free PMC article. No abstract available.
Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis.
van Breeschoten J, Wouters MWJM, Hilarius DL, Haanen JB, Blank CU, Aarts MJB, van den Berkmortel FWPJ, de Groot JB, Hospers GAP, Kapiteijn E, Piersma D, van Rijn RS, Suijkerbuijk KPM, Blokx WAM, Tije BJT, Veldt AAMV, Vreugdenhil A, Boers-Sonderen MJ, van den Eertwegh AJM. van Breeschoten J, et al. Br J Cancer. 2022 May;126(9):1362. doi: 10.1038/s41416-022-01772-z. Br J Cancer. 2022. PMID: 35256756 Free PMC article. No abstract available.
19 results